Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEmmanuel Bugarin-EstradaHBHenry BecerraRPRoger Pearse

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CAR-HEMATOTOX score predicts cytopenias and overall survival in refractory-relapsed multiple myeloma patients receiving immunotherapy.

Key Points

  • Overall, 39% of patients developed severe cytopenias after bispecific T-cell engager therapy, highlighting toxicity risks.
  • Therapeutic response rates were lower in patients with high CAR-HEMATOTOX scores, exhibiting only 11% complete response.
  • Progression-Free Survival was analyzed from the first BiTE dose, emphasizing survival outcomes in relation to CAR-HEMATOTOX scores.
  • Findings suggest that baseline hemoglobin level and lymphocyte count are critical indicators of patient risk with immunotherapy.

Cite This Study

Bugarin-Estrada et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de25https://doi.org/10.1182/blood-2025-5803
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)2025
  2. 2The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment2025
  3. 3Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  4. 4CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia2025 · 4 citations
  5. 5Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis2025